Precision medicine — medical care tailored to an individual — is set to revolutionise healthcare. However, the genetic studies and databases driving these advances, largely lack Māori and Pacific individuals. This creates a massive inequity and threatens to exacerbate the health inequities these populations face in Aoteoroa1. In our previous work we have used GWAS from European people to hone in on regions of the genome that associate with metabolic conditions in Māori and Pacific people. Due to the cost of sequencing we have been restricted to candidate gene approaches, focusing on a handful of protein-coding and copy number variants including a Mendelian effect variant within the lipid associated gene CETP. However, for polygenic metabolic conditions like T2D, CKD and gout, GWAS find that less than 10% of associated regions of the genome have causal mechanisms implicating a protein-coding variant. Instead, the majority of the polygenic associations are outside of the coding regions, in non-genic regions which are linked to the regulation of genes (enhancers). So while coding variants represent the ‘low hanging fruit’ of potential precision medicine targets, researchers and therapeutic companies are now turning their attention to the untapped potential of the non-coding genome for drug discovery. Large ‘omics databases like UKBB and GTEx make it possible to translate these non-coding regions into function however these datasets do not contain Māori and Pacific data. A “status quo” precision medicine approach threatens to exacerbate health inequities in Aoteoroa. To prevent this, it is critical that genetic approaches to precision medicine are undertaken in Aotearoa for Aotearoa. Thus we are beginning to apply an ‘omics strategy in collaboration with Variant Bio to discover clinically relevant Māori and Pacific genetics in the non-coding genome.